Tom's Investment Philosophy
“Investing in biotech is about identifying undervalued companies with big ideas, partnering on a journey with an exceptionally driven and honest management team, and building innovative solutions that create lasting value while making a meaningful impact on the world.”
THOMAS MALCOLM PH.D. - GENERAL PARTNER
Dr. Malcolm is a leader in the biotechnology field with over two decades of scientific expertise and strategic leadership. As the biotechnology lead for our venture capital firm, Dr. Malcolm guides our investment strategy into cutting-edge therapeutic platforms and breakthrough technologies. His multifaceted expertise covers a range of specialties including gene editing, drug delivery, oncology, structural biology, vaccine development, and biotherapeutics for human and animal health.
Currently serving as Chief Scientific and Innovations Officer at Caravan Biologix, Dr. Malcolm has led the company's advancements in novel gene delivery systems and the development of next-generation CAR constructs for targeted cancer therapies. The company combines AI-powered immunological synapse design with targeted biomimetic spherules - a groundbreaking technology that transforms therapeutic delivery with unparalleled precision and safety. Dr. Malcolm has been awarded multiple patents covering biomimetic spherule methods of composition, mechanisms of action, and engineering.
Dr. Malcolm also serves as Chief Executive and Scientific Officer at Kermode Biotechnologies, a company he co-founded to address critical challenges in vaccine development and biotechnology for infectious diseases. He has spearheaded the creation of the company’s Artificial Intelligence-driven ASFV vaccine platform and developed novel toxoid-based approaches for effective immune responses, for which he holds patents in ASFV toxoid engineering and vaccine development.
An accomplished innovator, Dr. Malcolm has filed patents for CRISPR gene editing techniques targeting latent viral reservoirs and cellular activation through engineered CAR constructs, demonstrating his leadership in developing disruptive technologies that drive the biotech industry forward. His work has enabled multiple start-ups to navigate complex R&D and regulatory landscapes, positioning them for success.
Dr. Malcolm has held senior executive positions, including Chief Scientific Officer at BioMark Diagnostics in Vancouver, British Columbia and Criterion BioScience in New York, NY. He is currently a board member at Gylden Pharmaceuticals in the United Kingdom and Scientific Advisor positions at Ferghana Partners In New York, NY and Cila Therapeutics in Boston, MA. Further, Dr. Malcolm holds a position as Strategic Advisor for Hippocrates Opportunity Fund in New York, NY.
His scientific rigor and strategic insights have been instrumental in securing Investigational New Drug (IND) applications, advancing molecular diagnostics, and leveraging AI-based design systems for protein and antibody engineering.
Dr. Malcolm earned his Ph.D. in Biochemistry & Molecular Biology from the University of British Columbia, Canada and has held postdoctoral research positions at Memorial Sloan Kettering Cancer Center and the Icahn School of Medicine at Mount Sinai. He has published in multiple high-impact scientific journals, contributing to advancements in virology, oncology, and immune-based therapies. With a proven track record of innovation, company building, and scientific discovery, Dr. Malcolm is committed to identifying and nurturing transformative biotech opportunities that create value for both investors and society.
